Unknown PHASE1 INTERVENTIONAL 1-arm NCT02364986

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RESI)

Sponsor: BfARM, Bonn

Conditions Relapsing-remitting Multiple Sclerosis

Updated 6 times since 2017 Last updated: Jun 2, 2016 Started: Jan 31, 2015 Primary completion: Jan 31, 2017 Completion: Jan 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02364986, this PHASE1 trial focuses on Relapsing-remitting Multiple Sclerosis and remains ongoing. Sponsored by BfARM, Bonn, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jul 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BfARM, Bonn
DZNE, Bonn
PD Dr. Marcus Müller

Data source: University Hospital, Bonn

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bonn, Germany